Andrea Sáez is an Investment Associate at Asabys, where she is responsible for sourcing and assessing biopharma opportunities from the scientific, development and business perspectives. She participates in deal structuring and negotiation as well as management of biopharma portfolio companies where she brings extensive expertise and hands-on experience in drug discovery and development.
Andrea holds a PhD in Biomedicine and a Master in Biotechnology Management from IE Business School. She has management experience in drug discovery and development as well as regulatory affairs. She received her PhD in Immunology at Pompeu Fabra University followed by postdoctoral experience in Oncology at Vall D’Hebron Hospital in Barcelona. She transitioned to drug development and regulatory affairs by joining a leading consultancy firm where she became Scientific and Regulatory Affairs Manager, being advisor to drug development companies on regulatory strategy for preclinical, CMC and early clinical activities. Later on, she became Drug Development Director at Pangaea Oncology, where she was responsible for drug discovery projects in-licensed from local and international institutions such as Cancer Research Technologies (UK). Most recently she was Drug Development Director at Senolytic Therapeutics. She accumulates extensive experience in translational research and drug development projects in the areas of immunology and oncology therapeutics, holds several publications in international peer-reviewed journals and is author of a patent application.